Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Yale Cancer Center
1344
mi
from
New Haven, CT
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Yale Cancer Center
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Florida Cancer Specialists
1206
mi
from
Fort Myers, FL
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Florida Cancer Specialists
1206
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Florida Cancer Specialists and Research Institute
1117
mi
from
Saint Petersburg, FL
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Florida Cancer Specialists and Research Institute
1117
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Central Indiana Cancer Centers
645
mi
from
Carmel, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Central Indiana Cancer Centers
645
mi
from
Carmel, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Indiana University
642
mi
from
Indianapolis, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Indiana University
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Indiana University Health Ball Memorial Hospital
688
mi
from
Muncie, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Indiana University Health Ball Memorial Hospital
688
mi
from
Muncie, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Community Hospital
608
mi
from
Munster, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Community Hospital
608
mi
from
Munster, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Floyd Memorial Cancer Center of Indiana
653
mi
from
New Albany, IN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Floyd Memorial Cancer Center of Indiana
653
mi
from
New Albany, IN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Owsley Brown Frazier Cancer Center-Louisville Downtown
656
mi
from
Louisville, KY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Owsley Brown Frazier Cancer Center-Louisville Downtown
656
mi
from
Louisville, KY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Tulane University
697
mi
from
New Orleans, LA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Tulane University
697
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Massachusetts General Hospital
1443
mi
from
Boston, MA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Ann Arbor Hematology Oncology Associates
808
mi
from
Ann Arbor, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Ann Arbor Hematology Oncology Associates
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Sparrow Regional Cancer Center
779
mi
from
Lansing, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Sparrow Regional Cancer Center
779
mi
from
Lansing, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Metro Health Cancer Center
730
mi
from
Wyoming, MI
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Metro Health Cancer Center
730
mi
from
Wyoming, MI
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Southeast Nebraska Cancer Center
220
mi
from
Lincoln, NE
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Southeast Nebraska Cancer Center
220
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Broome Oncology, LLC
1193
mi
from
Johnson City, NY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Broome Oncology, LLC
1193
mi
from
Johnson City, NY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Memorial Sloan-Kettering Cancer Center
1289
mi
from
New York, NY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Memorial Sloan-Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
University of Rochester
1121
mi
from
Rochester, NY
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
University of Rochester
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Blumenthal Cancer Center
958
mi
from
Charlotte, NC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Blumenthal Cancer Center
958
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Piedmont Hematology-Oncology Associates
973
mi
from
Winston-Salem, NC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Piedmont Hematology-Oncology Associates
973
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Oncology Hematology Care
734
mi
from
Cincinnati, OH
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Oncology Hematology Care
734
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Signal Point Clinical Research Center, LLC
734
mi
from
Middletown, OH
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Signal Point Clinical Research Center, LLC
734
mi
from
Middletown, OH
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Willamette Valley Cancer Institute/Research Ctr
1382
mi
from
Eugene, OR
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Willamette Valley Cancer Institute/Research Ctr
1382
mi
from
Eugene, OR
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Providence Portland Medical Center
1383
mi
from
Portland, OR
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Providence Portland Medical Center
1383
mi
from
Portland, OR
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Charleston Hematology Oncology Associates, PA
1056
mi
from
Charleston, SC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Charleston Hematology Oncology Associates, PA
1056
mi
from
Charleston, SC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Cancer Centers of the Carolinas - Grove Commons
882
mi
from
Greenville, SC
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Cancer Centers of the Carolinas - Grove Commons
882
mi
from
Greenville, SC
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Chattanooga Oncology Hematology Associates
722
mi
from
Chattanooga, TN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Chattanooga Oncology Hematology Associates
722
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Sarah Cannon Cancer Center
618
mi
from
Nashville, TN
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Sarah Cannon Cancer Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Texas Oncology - Arlington South
351
mi
from
Arlington, TX
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Texas Oncology - Arlington South
351
mi
from
Arlington, TX
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Texas Oncology-Baylor Charles A. Sammons Cancer Center
347
mi
from
Dallas, TX
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Texas Oncology-Baylor Charles A. Sammons Cancer Center
347
mi
from
Dallas, TX
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Texas Oncology-Tyler
398
mi
from
Tyler, TX
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Texas Oncology-Tyler
398
mi
from
Tyler, TX
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
University of Utah Hospital and Clinics
777
mi
from
Salt Lake City, UT
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
University of Utah Hospital and Clinics
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Virginia Cancer Institute
1106
mi
from
Richmond, VA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Virginia Cancer Institute
1106
mi
from
Richmond, VA
Click here to add this to my saved trials
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2012
Puget Sound Cancer Centers
1415
mi
from
Edmonds, WA
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2012
Puget Sound Cancer Centers
1415
mi
from
Edmonds, WA
Click here to add this to my saved trials
Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
Status: Enrolling
Updated:  7/24/2012
The Miriam Hospital
1424
mi
from
Providence, RI
Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer
Status: Enrolling
Updated: 7/24/2012
The Miriam Hospital
1424
mi
from
Providence, RI
Click here to add this to my saved trials
Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/24/2012
LSU Health Sciences Center, 1501 Kings Highway
428
mi
from
Shreveport, LA
Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/24/2012
LSU Health Sciences Center, 1501 Kings Highway
428
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test
A Prospective Study of Clinical Outcomes for the Pathwork® Tissue of Origin Test
Status: Enrolling
Updated:  7/24/2012
Cedar Associates LLC
1329
mi
from
Menlo Park, CA
A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test
A Prospective Study of Clinical Outcomes for the Pathwork® Tissue of Origin Test
Status: Enrolling
Updated: 7/24/2012
Cedar Associates LLC
1329
mi
from
Menlo Park, CA
Click here to add this to my saved trials
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  7/25/2012
TGen Drug Development Services
842
mi
from
Scottsdale, AZ
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 7/25/2012
TGen Drug Development Services
842
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  7/25/2012
Mayo Clinic Arizona
835
mi
from
Scottsdale, AZ
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 7/25/2012
Mayo Clinic Arizona
835
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  7/25/2012
St Mary's Medical Center
775
mi
from
San Francisco, CA
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 7/25/2012
St Mary's Medical Center
775
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  7/25/2012
Indiana University Simon Cancer Center
642
mi
from
Indianapolis, IN
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 7/25/2012
Indiana University Simon Cancer Center
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  7/25/2012
Mayo Clinic Rochester
515
mi
from
Rochester, MN
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 7/25/2012
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  7/25/2012
Sarah Cannon Research Institute
618
mi
from
Nashville, TN
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 7/25/2012
Sarah Cannon Research Institute
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  7/25/2012
Mary Crowley Cancer Research Centers
347
mi
from
Dallas, TX
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 7/25/2012
Mary Crowley Cancer Research Centers
347
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/26/2012
Virginia G. Piper Cancer Center
843
mi
from
Scottsdale, AZ
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/26/2012
Virginia G. Piper Cancer Center
843
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/26/2012
Esanex Investigational Site
619
mi
from
Nashville, TN
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/26/2012
Esanex Investigational Site
619
mi
from
Nashville, TN
Click here to add this to my saved trials
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  7/30/2012
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 7/30/2012
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
683
mi
from
Birmingham, AL
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
1168
mi
from
Los Angeles, CA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials